Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.
We are a diverse group of physicians & scientists with expertise in cell biology, pharmacology, genetics, immunology and computational biology. We are currently recruiting at all levels - if you would like to join our team, please contact us.
Meet the TeamOur collaboration with the Weiskopf lab on redirecting macrophages to target persister cells in oncogene-addicted lung cancers is now published in JCI: Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated…
Go to NewsHideko presents on her most recent work "APOBEC3A drives tumor evolution through activation of ERVs in non-small cell lung cancer" at the the 5th International Conference on Base Editing, Prime…
Go to NewsWe are looking for people to partner with us in our mission to improve treatments for patients with lung cancer.
Join Us Support UsWe are privileged to partner with a number of individuals and organizations who support our research. We are grateful for their dedication to helping us in the fight against lung cancer.